Farydak made history by being the first histone deacetylase inhibitor with epigenetic activity to be approved in the European Union, offering another treatment option for those with multiple myeloma.
Farydak made history by being the first histone deacetylase inhibitor with epigenetic activity to be approved in the European Union, offering another treatment option for those with multiple myeloma.
Share this Article
Recommended